Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals (NASDAQ: REGN) is a leading biotechnology innovator developing transformative treatments for serious diseases through advanced platforms like VelociSuite®. This page serves as the definitive source for official company announcements, research milestones, and therapeutic developments.
Investors and medical professionals will find curated updates including FDA approvals, clinical trial results, partnership announcements, and financial reports. Our aggregation ensures timely access to Regeneron's progress in oncology, immunology, rare diseases, and ophthalmic therapies.
All content is sourced directly from Regeneron's communications and verified financial disclosures. Bookmark this page to monitor the company's pipeline advancements, regulatory updates, and strategic collaborations that drive biopharmaceutical innovation.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced upcoming investor events for September 2024. These include presentations at two major healthcare conferences: the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 and the 2024 Wells Fargo Healthcare Conference on September 5. Additionally, Regeneron will host an oncology-focused webcast on September 16, coinciding with the European Society for Medical Oncology (ESMO) 2024 conference. This webcast will provide updates on the company's oncology portfolio. All events will be accessible via Regeneron's investor relations website, with replays and transcripts available for at least 30 days after each event.
Regeneron Pharmaceuticals reported strong Q2 2024 financial results, with total revenue up 12% to $3.55 billion. EYLEA HD and EYLEA U.S. net sales increased 2% to $1.53 billion, including $304 million from EYLEA HD. Dupixent global net sales grew 27% to $3.56 billion, while Libtayo global net sales rose 42% to $297 million. GAAP diluted EPS increased 46% to $12.41, and non-GAAP diluted EPS rose 13% to $11.56. The European Commission approved Dupixent for uncontrolled COPD, marking its first regulatory approval for this indication. Regeneron's pipeline progress includes advancing over 35 product candidates, with key developments in oncology and other therapeutic areas.
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced the winners of its 12th annual Regeneron Prize for Creative Innovation. Christopher Giuliano and Julian Roessler, both Ph.D. candidates at MIT's Whitehead Institute for Biomedical Research, were awarded $50,000 each, plus a $10,000 grant for their institution. Six other finalists received $5,000 awards.
The Regeneron Prize recognizes outstanding early-career scientists in biomedical research. Nominees from leading U.S. research universities propose 'dream projects' evaluated on scientific merit, creativity, and originality. Since 2013, the program has supported early-career scientists with over $1.7 million in awards.
Regeneron's commitment to fostering the next generation of scientific innovators is evident in its broader STEM initiatives, which have supported over 2.4 million students since 2020 through various programs and competitions.
Regeneron Pharmaceuticals and Sanofi announced that the European Commission has approved Dupixent (dupilumab) as the first targeted therapy for adults with uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils. This approval is based on two Phase 3 trials, BOREAS and NOTUS, which showed significant reductions in COPD exacerbations and improvements in lung function and quality of life. The trials demonstrated a 30% and 34% reduction in annual exacerbation rates and notable lung function improvements.
This marks the first new treatment for COPD in over a decade, offering a novel option for approximately 220,000 adults in the EU. Dupixent's approval also represents its sixth indication in the EU and seventh globally. Further regulatory submissions are under review in other countries, including the U.S., China, and Japan.
The efficacy results showed improvements in FEV1 by 160 mL and 139 mL at 12 weeks, compared to placebo improvements of 77 mL and 57 mL. Safety results were consistent with known profiles, with common side effects including injection site reactions and conjunctivitis.
Regeneron Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended conditional marketing authorization for odronextamab to treat relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). The recommendation is based on data from Phase 1 and Phase 2 trials showing robust and durable response rates. The European Commission is expected to make a final decision in the coming months. FL and DLBCL are common subtypes of B-cell non-Hodgkin lymphoma, with significant relapse rates after initial treatments. In Europe, approximately 15,000 FL and 31,000 DLBCL cases are diagnosed annually. The most common serious adverse reactions reported were cytokine release syndrome, pneumonia, COVID-19, and pyrexia. Odronextamab has not yet been approved by any regulatory authority and is still under clinical development.
Regeneron Pharmaceuticals announced it will release its Q2 2024 financial and operating results on August 1, 2024, before U.S. markets open. The company will hold a conference call and webcast at 8:30 AM ET on the same day. Investors can access the webcast via Regeneron's investor relations page. For telephone participation, pre-registration is required. A replay and transcript of the call will be available on the company's website for a minimum of 30 days.
Regeneron Pharmaceuticals and Sanofi have announced positive Phase 3 trial results for Dupixent (dupilumab) in treating eosinophilic esophagitis (EoE) in children aged 1 to 11 years. The study, published in the New England Journal of Medicine, showed that a higher proportion of patients receiving weight-tiered higher dose Dupixent achieved significant improvements in EoE symptoms compared to placebo at week 16. These improvements were sustained for up to one year. The data supported the FDA's approval of Dupixent for this age group and are under review by the European Medicines Agency. The trial also found that Dupixent led to improvements in body weight for age percentile and had a safety profile consistent with its use in older patients.
Regeneron Pharmaceuticals announced 14-month follow-up data from the LINKER-MM1 trial on linvoseltamab for relapsed/refractory multiple myeloma. The trial showed a 71% overall response rate (ORR) and 50% complete response (CR) or better. Median duration of response (DoR) was 29 months, and median overall survival (OS) was 31 months. Safety data were consistent with previous results, with cytokine release syndrome (CRS) in 46% of patients as the most common adverse event. Linvoseltamab showed better outcomes compared to real-world standard care. The U.S. FDA has given it Fast Track Designation and Priority Review, with a decision expected by August 22, 2024. The drug is also under review by the European Medicines Association and is in a Phase 3 confirmatory trial.
Regeneron Pharmaceuticals and Sanofi announced FDA approval of Kevzara® (sarilumab) for treating active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg or more.
This expands Kevzara’s use beyond adult chronic inflammatory conditions like rheumatoid arthritis and polymyalgia rheumatica. The approval is based on comprehensive studies and pharmacokinetic data from adults and pediatric patients.
Common adverse reactions include nasopharyngitis, neutropenia, and upper respiratory tract infection. KevzaraConnect® provides support services to help patients access the treatment.
Regeneron Pharmaceuticals and Sanofi announced that Dupixent (dupilumab) has been recommended for EU approval by the CHMP as an add-on maintenance treatment for adults with uncontrolled COPD marked by raised blood eosinophils. This recommendation is based on Phase 3 trials (BOREAS and NOTUS), where Dupixent showed a significant reduction in annualized moderate or severe acute COPD exacerbations by up to 34% compared to placebo and improved lung function and quality of life over 52 weeks. If approved, Dupixent would be the first targeted therapy for COPD in the EU and the first new treatment approach for COPD in over a decade. The European Commission's final decision is expected within months.
